Allogeneic Progenitor Cell Equipment & Supplies
58 equipment items found
Manufactured by:Stemedica Cell Technologies, Inc. based inSan Diego, CALIFORNIA (USA)
There are two types of cells currently used for investigating progenitor cell therapies for degenerative diseases: autologous and allogeneic. Autologous progenitor cells are derived from the patient being treated. They are retrieved surgically, expanded, and transplanted back into the same ...
by:Vor Biopharma based inCambridge, MASSACHUSETTS (USA)
VCAR33ALLO uses allogeneic healthy donor-derived cells. There has been an increasing appreciation for the value of cell phenotype in CAR-T approaches, and HLA-matched healthy donor cells are a potentially superior cell phenotype with improved persistence and in vivo expansion ...
Manufactured by:healiva SA based inLugano, SWITZERLAND
Our scalable treatment for chronic leg ulcers that are not responding to standard of care, using automated ...
by:ABEC, INC. based inBethlehem, PENNSYLVANIA (USA)
Our conditionally-immortalized allogeneic cell lines are derived from hematopoietic stem cells and allows us to eliminate the need for recurring donors. From a single cell line, we can produce unlimited quantities of consistent fully-functional cells with targeted ...
Manufactured by:TC BioPharm based inHolytown, UNITED KINGDOM
TCB007 is an unmodified allogeneic gamma delta T cell product, being used for the treatment of COVID-19. This product is at the CTA application stage and is expected to enter phase 1 trials in summer 2020. ...
by:Chimeric Therapeutics based inCarlton South, AUSTRALIA
CHM 1301 (CLTX CAR NK) will be developed on the next generation CORE-NK platform leveraging our CLTX Chimeric Antigen ...
by:Chimeric Therapeutics based inCarlton South, AUSTRALIA
The next generation CORE-NK platform will integrate additional activation and expansion features to further optimize the cancer-fighting power of the CORE-NK platform cells. Development of the next generation CORE-NK platform will be as a combination therapy for blood ...
by:Caribou Biosciences, Inc. based inBerkeley, CALIFORNIA (USA)
Our next-generation chRDNA genome-editing platform is the foundation for the development of differentiated allogeneic cell therapies. Our chRDNA technology enables multiple genome edits, including multiplex gene insertions, with a high degree of specificity and lower levels of off-target editing than first generation CRISPR-Cas9. ...
by:Chimeric Therapeutics based inCarlton South, AUSTRALIA
CHM 3301 (Undisclosed CAR NK) will be developed on the next generation CORE-NK platform leveraging a currently undisclosed Chimeric Antigen ...
by:Chimeric Therapeutics based inCarlton South, AUSTRALIA
CHM 2301 (CDH17 CAR NK) will be developed on the next generation CORE-NK platform leveraging our CDH17 Chimeric Antigen ...
Manufactured by:Celularity Inc. based inFlorham Park, NEW JERSEY (USA)
Celularity’s unique technology realizes the full promise of cell therapies by harnessing the immunomodulatory and regenerative properties of the postpartum ...
Manufactured by:Bone Therapeutics SA based inMont-St-Guibert, BELGIUM
Bone Therapeutics is bringing a unique value proposition by developing a range of innovative bone cell therapy products administrable via a minimally invasive technique. ...
by:Scinogy Pty Ltd based inVictoria, AUSTRALIA
Scinogy's allogeneic cell processing systems are uniquely configured to realize economies of scale and optimize facility, equipment and staff utilization. These automated and integrated systems are designed to consistently processes multiple batches on any given day. Closed, single use kits enable parallel processing of multiple batches in a common, lower grade clean room whilst centralized ...
Manufactured by:Khloris Biosciences, Inc. based inMountain View, CALIFORNIA (USA)
Khloris' iPSCs are optimized to generate high-functioning cardiomyocytes, enabling development of an allogeneic source of donor cells for patients with damaged heart ...
by:Chimeric Therapeutics based inCarlton South, AUSTRALIA
The CORE-NK platform is a transformative platform technology for Chimeric enabling the accelerated development of multiple next generation, off the shelf NK and CAR-NK products. Natural killer cells are found in our bodies naturally and are able to recognize and kill cancer cells – but are not robust and active enough to overcome cancer as it grows. CORE-NK platform cells are made by ...
Manufactured by:Senti Biosciences based inSouth San Francisco, CALIFORNIA (USA)
Pursuing an Unmet Need in the Treatment of CRC - SENTI-401 is designed to more precisely target and eliminate colorectal cancer (CRC) cells while sparing healthy cells elsewhere in the body. Our vision is a potential medicine that more effectively treats patients with colorectal ...
Manufactured by:DiscGenics, Inc. based inSalt Lake City, UTAH (USA)
DiscGenics uses its patented allogeneic cell culture manufacturing technology to isolate cells from donated adult human intervertebral disc tissue and induce a progenitor state. These proprietary Discogenic Cells are then expanded for therapeutic application, combined with a delivery vehicle and cryopreserved for ...
Manufactured by:ASC Therapeutics based inMilpitas, CALIFORNIA (USA)
Stem cells, including inducible pluripotent stem cells, mesenchymal stem cells (MSCs) and other primary pluripotent cells, hold the potential to treat a variety of diseases. We are currently focusing on developing an allogeneic decidua stromal cells (DSCs)-based platform to treat severe immune-mediated diseases. Our pre-clinical and clinical data suggest that the immunomodulatory activity of DSCs ...
by:Vor Biopharma based inCambridge, MASSACHUSETTS (USA)
We believe VOR33 and VCAR33 could be highly synergistic as a Treatment System, potentially enabling prolonged remissions or cures in the post-transplant setting. We intend to investigate the VOR33/VCAR33 Treatment System, entailing VOR33 eHSC therapy followed by VCAR33 as a companion therapeutic, initially for transplant-eligible patients suffering from AML. We believe VCAR33 could be a potent ...
Manufactured by:Senti Biosciences based inSouth San Francisco, CALIFORNIA (USA)
The product profile of SENTI-301 has the potential to promote expansion and persistence of NK cells, and activate and recruit the body’s own immune cells into the solid tumor microenvironment for enhanced anti-tumor activity. ...